GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeOne Medicines Ltd (SHSE:688235) » Definitions » Cash Flow from Others

BeOne Medicines (SHSE:688235) Cash Flow from Others : ¥414 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is BeOne Medicines Cash Flow from Others?

BeOne Medicines's cash flow from others for the three months ended in Mar. 2025 was ¥-54 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Mar. 2025 was ¥414 Mil.


BeOne Medicines Cash Flow from Others Historical Data

The historical data trend for BeOne Medicines's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeOne Medicines Cash Flow from Others Chart

BeOne Medicines Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Others
Get a 7-Day Free Trial Premium Member Only Premium Member Only -137.23 -83.49 23.05 -2,578.96 159.88

BeOne Medicines Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -115.39 -125.78 -47.67 640.99 -53.96

BeOne Medicines Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥414 Mil.

BeOne Medicines Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of BeOne Medicines's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


BeOne Medicines Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeOne Medicines Headlines

No Headlines